| |
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metas . . .
PHRR200921-002949 |
Ongoing |
21 Sep 2020 |
| |
Efficacy and Safety of Vitex negundo for MILD COVID-19 Trial (EVICT Program)
PHRR210126-002992 |
Ongoing |
26 Jan 2021 |
| |
One Time Application of 80% Trichloroacetic Acid Peel versus 65% Trichloroacetic Acid Peel in the Clearance of Raised Seborrheic Keratosis in Filipino Patients: A Randomized Controlled Trial . . .
PHRR201007-003019 |
Ongoing |
07 Oct 2020 |
| |
A Phase 1b Randomized, Double-blind, Placebo-controlled, Multiple Ascending-dose Study of EQ001 in Subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis . . .
PHRR201007-003022 |
Ongoing |
07 Oct 2020 |
| |
A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and N . . .
PHRR201012-003024 |
Ongoing |
12 Oct 2020 |
| |
Evaluation of Philippine Mango pectin as tablet binder for formulated Sambong tablet
PHRR201019-003047 |
Ongoing |
19 Oct 2020 |
| |
ROSuvastatin Evaluation as a Tuberculosis Treatment Adjunct
PHRR201029-003106 |
Pending |
29 Oct 2020 |
| |
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Meter . . .
PHRR210205-003330 |
Ongoing |
05 Feb 2021 |
| |
A Phase 3 Study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Front-Line, PD-L1-Positive, Locally Advanced or Metastatic Non-Sma . . .
PHRR210222-003371 |
Ongoing |
22 Feb 2021 |
| |
Virgin Coconut Oil as Adjunctive Therapy for Hospitalized COVID-19 Patients
PHRR210303-003392 |
Ongoing |
03 Mar 2021 |
| |
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma . . .
PHRR210310-003410 |
Ongoing |
10 Mar 2021 |
| |
A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 52-Week, Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With . . .
PHRR210504-003526 |
Ongoing |
04 May 2021 |
| |
A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan(T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexe . . .
PHRR210611-003638 |
Ongoing |
11 Jun 2021 |
| |
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) . . .
PHRR210706-003703 |
Ongoing |
06 Jul 2021 |
| |
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) . . .
PHRR210721-003751 |
Pending |
21 Jul 2021 |
| |
A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients . . .
PHRR210811-003803 |
Pending |
11 Aug 2021 |
| |
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Dec . . .
PHRR210911-003890 |
Ongoing |
11 Sep 2021 |
| |
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants with Active Systemic Lupus Erythematosus (AZALEA) . . .
PHRR211004-003968 |
Ongoing |
04 Oct 2021 |
| |
A Phase 3 Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy. . . .
PHRR211007-003996 |
Ongoing |
07 Oct 2021 |
| |
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cance . . .
PHRR211212-004147 |
Ongoing |
12 Dec 2021 |
| |
In vitro Larvicidal Activity of Allium ampeloprasum L. ("sakurab") Against Aedes aegypti L. Larvae . . .
PHRR220211-004291 |
Completed |
11 Feb 2022 |
| |
EFFECTIVENESS AND SAFETY OF SOYBEAN 4% OINTMENT VERSUS CLOBETASOL PROPIONATE 0.05% OINTMENT IN MILD PLAQUE PSORIASIS (BSA <3%): A RANDOMIZED CLINICAL TRIAL . . .
PHRR220228-004383 |
Ongoing |
28 Feb 2022 |
| |
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens ofMEDI3506 in Participants with Sy . . .
PHRR220419-004549 |
Pending |
19 Apr 2022 |